Ganoderic acid HCAS# 98665-19-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 98665-19-1 | SDF | Download SDF |
| PubChem ID | 471005 | Appearance | Powder |
| Formula | C32H44O9 | M.Wt | 572.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R,6S)-6-[(3S,5R,10S,12S,13R,14R,17R)-12-acetyloxy-3-hydroxy-4,4,10,13,14-pentamethyl-7,11,15-trioxo-1,2,3,5,6,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid | ||
| SMILES | CC(CC(=O)CC(C)C(=O)O)C1CC(=O)C2(C1(C(C(=O)C3=C2C(=O)CC4C3(CCC(C4(C)C)O)C)OC(=O)C)C)C | ||
| Standard InChIKey | YCXUCEXEMJPDRZ-QWPKPZHNSA-N | ||
| Standard InChI | InChI=1S/C32H44O9/c1-15(11-18(34)12-16(2)28(39)40)19-13-23(37)32(8)24-20(35)14-21-29(4,5)22(36)9-10-30(21,6)25(24)26(38)27(31(19,32)7)41-17(3)33/h15-16,19,21-22,27,36H,9-14H2,1-8H3,(H,39,40)/t15-,16+,19+,21-,22-,27+,30-,31-,32-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ganoderic acid H is a potent antitumour agent, it mediates its biological effects through the inhibition of transcription factors AP-1 and NF-kappaB, resulting in the down-regulation of expression of Cdk4. |
| Targets | NF-kB | AP-1 | CDK |
| In vitro | Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling.[Pubmed: 18425349]Int J Mol Med. 2008 May;21(5):577-84.Structurally related lanostane-type triterpenes, ganoderic acid A, F and H (GA-A, GA-F, Ganoderic acid H), were identified in an oriental medicinal mushroom Ganoderma lucidum. |
| Structure Identification | Nat Prod Res. 2014;28(24):2264-72.Extraction optimisation and isolation of triterpenoids from Ganoderma lucidum and their effect on human carcinoma cell growth.[Pubmed: 25032738]The response surface methodology was used to optimise the extraction conditions of Ganoderma lucidum based on a Box-Behnken design. |
Ganoderic acid H Dilution Calculator
Ganoderic acid H Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7461 mL | 8.7306 mL | 17.4611 mL | 34.9223 mL | 43.6529 mL |
| 5 mM | 0.3492 mL | 1.7461 mL | 3.4922 mL | 6.9845 mL | 8.7306 mL |
| 10 mM | 0.1746 mL | 0.8731 mL | 1.7461 mL | 3.4922 mL | 4.3653 mL |
| 50 mM | 0.0349 mL | 0.1746 mL | 0.3492 mL | 0.6984 mL | 0.8731 mL |
| 100 mM | 0.0175 mL | 0.0873 mL | 0.1746 mL | 0.3492 mL | 0.4365 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Lucidenic acid D2
Catalog No.:BCN8202
CAS No.:98665-16-8
- Ganoderic Acid J
Catalog No.:BCN8436
CAS No.:100440-26-4
- Ganoderic acid F
Catalog No.:BCN3037
CAS No.:98665-14-6
- Methyl ganoderate H
Catalog No.:BCN3258
CAS No.:98665-11-3
- Zedoarondiol
Catalog No.:BCN3560
CAS No.:98644-24-7
- Nitrocaramiphen hydrochloride
Catalog No.:BCC6655
CAS No.:98636-73-8
- Sarmentocymarin
Catalog No.:BCN7489
CAS No.:98633-61-5
- (S)-(-)-Bay K 8644
Catalog No.:BCC7108
CAS No.:98625-26-4
- Schisandrone
Catalog No.:BCN3316
CAS No.:98619-25-1
- Cryptanoside A
Catalog No.:BCN7481
CAS No.:98570-81-1
- Sominone
Catalog No.:BCN8006
CAS No.:98569-64-3
- 4-Chloro-6-iodoquinazoline
Catalog No.:BCC8703
CAS No.:98556-31-1
- Ganoderic acid I
Catalog No.:BCN2865
CAS No.:98665-20-4
- Ganolucidic acid A
Catalog No.:BCN2444
CAS No.:98665-21-5
- Ganoderic acid G
Catalog No.:BCN2915
CAS No.:98665-22-6
- Dregeoside Da1
Catalog No.:BCN4764
CAS No.:98665-65-7
- Dregeoside Ga1
Catalog No.:BCN4548
CAS No.:98665-66-8
- ATP disodium salt
Catalog No.:BCC5160
CAS No.:987-65-5
- Ropivacaine HCl
Catalog No.:BCC4841
CAS No.:98717-15-8
- Paeonilactone C
Catalog No.:BCN3964
CAS No.:98751-77-0
- Paeonilactone B
Catalog No.:BCN3963
CAS No.:98751-78-1
- Paeonilactone A
Catalog No.:BCN3967
CAS No.:98751-79-2
- Latifoline N-oxide
Catalog No.:BCN1979
CAS No.:98752-06-8
- Isothymusin
Catalog No.:BCN4532
CAS No.:98755-25-0
Extraction optimisation and isolation of triterpenoids from Ganoderma lucidum and their effect on human carcinoma cell growth.[Pubmed:25032738]
Nat Prod Res. 2014;28(24):2264-72.
The response surface methodology was used to optimise the extraction conditions of Ganoderma lucidum based on a Box-Behnken design. A quadratic model sufficiently simulated the response of Ganoderic acid H with a determination coefficient (R(2)) of 0.98. The optimal condition for extracting triterpenoids was determined to be 100.00% ethanol at 60.22 degrees C for 6.00 h, under which the yield of the reference triterpenoid Ganoderic acid H increased from 0.88 to 2.09 mg/g powder. Following extraction, triterpenoid-enriched fraction was further isolated into 23 fractions, and 7 fractions were identified as ganoderic acids A, B, D, G, H and I and ganoderenic acid D. Of the seven triterpenoids, ganoderenic acid D was most cytotoxic with IC50 values of 0.14 +/- 0.01, 0.18 +/- 0.02 and 0.26 +/- 0.03 mg/mL in Hep G2, Hela and Caco-2 cells, respectively. While ganoderic acids A, G and H were relatively non-cytotoxic. The variation of inhibitory effects for these triterpenoids was likely related to their chemical structures.
Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling.[Pubmed:18425349]
Int J Mol Med. 2008 May;21(5):577-84.
Structurally related lanostane-type triterpenes, ganoderic acid A, F and H (GA-A, GA-F, GA-H), were identified in an oriental medicinal mushroom Ganoderma lucidum. In the present study we evaluated the effect of GA-A, GA-H and GA-F on highly invasive human breast cancer cells. We showed that GA-A and GA-H suppressed growth (cell proliferation and colony formation) and invasive behavior (adhesion, migration and invasion) of MDA-MB-231 cells. Our results suggest that GA-A and GA-H mediate their biological effects through the inhibition of transcription factors AP-1 and NF-kappaB, resulting in the down-regulation of expression of Cdk4 and the suppression of secretion of uPA, respectively. Furthermore, the activity of ganoderic acids is linked to the hydroxylation in the position 7 and 15 (GA-A) and 3 (GA-H) in their triterpene lanostane structure. In conclusion, hydroxylated triterpenes from G. lucidum could be promising natural agents for the therapy of invasive breast cancers.
